Two major drug trials conclude there was little risk from the AMD drug Lucentis (ranibizumab). Yet a Mayo Clinic ophthalmologist began to note something concerning in some of her patients: an increase in pressure inside the eye. It led to a retrospective study and findings that was presented at last month’s American Academy of Ophthalmology meeting.
Sophie Bakri, MD, had been treating patients in her clinic with FDA-approved ranibizumab, when she began noticing a change in some patients. “I was treating patients and measuring pressures, and I was surprised to see that in some of these people, their intraocular pressure was higher, and they didn’t have a diagnosis of glaucoma,” Dr. Bakri says. “So, why did the pressure go up? Was it from the drug itself, or the actual injection? Is this real? You don’t know if it’s a fluke unless you go back and look at the clinical trials. I took a closer look at the pooled data.”
Entire article available at: http://www.revophth.com/content/d/review_news/i/1688/c/30881/
